Autocrine Prostaglandin E2 Signaling Promotes Tumor Cell Survival and Proliferation in Childhood Neuroblastoma by Rasmuson, Agnes et al.
Autocrine Prostaglandin E2 Signaling Promotes Tumor
Cell Survival and Proliferation in Childhood
Neuroblastoma
Agnes Rasmuson
1*, Anna Kock
1, Ole Martin Fuskeva ˚g
2, Bjo ¨rn Kruspig
3, Jaione Simo ´n-Santamarı ´a
4,
Vladimir Gogvadze
3, John Inge Johnsen
1, Per Kogner
1., Baldur Sveinbjo ¨rnsson
1,5.
1Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden, 2Department of Clinical Pharmacology,
University Hospital of North Norway, Tromsø, Norway, 3Division of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 4Vascular
Biology Research Group, Faculty of Medicine, University of Tromsø, Tromsø, Norway, 5Division of Immunology, Faculty of Health Sciences, University of Tromsø, Tromsø,
Norway
Abstract
Background: Prostaglandin E2 (PGE2) is an important mediator in tumor-promoting inflammation. High expression of
cyclooxygenase-2 (COX-2) has been detected in the embryonic childhood tumor neuroblastoma, and treatment with COX
inhibitors significantly reduces tumor growth. Here, we have investigated the significance of a high COX-2 expression in
neuroblastoma by analysis of PGE2 production, the expression pattern and localization of PGE2 receptors and intracellular
signal transduction pathways activated by PGE2.
Principal Findings: A high expression of the PGE2 receptors, EP1, EP2, EP3 and EP4 in primary neuroblastomas, independent
of biological and clinical characteristics, was detected using immunohistochemistry. In addition, mRNA and protein
corresponding to each of the receptors were detected in neuroblastoma cell lines. Immunofluorescent staining revealed
localization of the receptors to the cellular membrane, in the cytoplasm, and in the nuclear compartment. Neuroblastoma
cells produced PGE2 and stimulation of serum-starved neuroblastoma cells with PGE2 increased the intracellular
concentration of calcium and cyclic AMP with subsequent phosphorylation of Akt. Addition of 16,16-dimethyl PGE2
(dmPGE2) increased cell viability in a time, dose- and cell line-dependent manner. Treatment of neuroblastoma cells with a
COX-2 inhibitor resulted in a diminished cell growth and viability that was reversed by the addition of dmPGE2. Similarly,
PGE2 receptor antagonists caused a decrease in neuroblastoma cell viability in a dose-dependent manner.
Conclusions: These findings demonstrate that PGE2 acts as an autocrine and/or paracrine survival factor for neuroblastoma
cells. Hence, specific targeting of PGE2 signaling provides a novel strategy for the treatment of childhood neuroblastoma
through the inhibition of important mediators of tumor-promoting inflammation.
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Introduction
Inflammatory cells and mediators are critical components of
the tumor microenvironment. Many cancer cells have adapted
inflammatory signaling molecules as autocrine and/or paracrine
survival factors. Arachidonic acid-derived lipid mediators are very
potent signaling molecules that are important in the inflammatory
process and implicated in tumorigenesis. Conversion of arachi-
donic acid by the cyclooxygenase (COX) enzymes results in the
production of prostaglandins and thromboxane. A large body of
evidence has shown that COX-2 is often highly expressed in adult
cancers of epithelial origin, and has been implicated in resistance
to apoptosis, promotion of proliferation, increased tumor inva-
siveness and angiogenesis as well as decreased immunosurveillance
[1]. Neuroblastoma, an embryonic tumor of early childhood, is
enriched in arachidonic acid, and expresses high levels of COX-2
[2,3]. Neuroblastoma arises from immature cells of the developing
sympathetic nervous system, with primary tumors in the adrenal
gland medulla or in paravertebral ganglia. The tumors exhibit
very heterogeneous clinical behaviour with some congenital
tumors spontaneously regressing even without any treatment
whereas the majority of neuroblastoma patients present with
aggressive metastatic tumors with poor prognosis despite very
intensive therapy [4]. Therapeutic inhibition of the COX enzymes
in neuroblastoma induces apoptosis, suppresses tumor growth,
reduces angiogenesis and potentiates the toxic effect of cytostatic
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29331drugs [3,5–7]. Inhibition of this pathway may represent a novel
treatment strategy for neuroblastoma patients not cured today.
However, clinical studies have raised concerns about the potential
adverse side effects of NSAIDs in adults [8]. Also, COX inhibitors
have shown to possess off-target effects that contribute to cancer
inhibition [9]. Therefore, further investigation of a high COX-2
expression in neuroblastoma, and the possibility of a more specific
targeting of this pathway is highly warranted.
Upon cellular stimuli arachidonic acid is released from membrane
phospholipids by cytosolic phospholipase A2(cPLA2). Arachidonic acid
is then converted to prostaglandin H2 (PGH2) in a two-step reaction
catalysed by either of the two COX isoforms, the constitutively active
COX-1 or the inducible COX-2. PGH2is further metabolized into the
different prostaglandins by specific synthases [1]. Newly formed PGE2
can either act on receptors located near their site of synthesis or be
transported out of the cell to act in an autocrine or paracrine manner
[1,10]. PGE2 exerts its effects by interacting with a subfamily of four
distinct G-protein-coupled receptors (GPCR) designated EP1, EP2,
EP3 and EP4 [11]. The EP1 receptor causes upon stimulation an
increase of intracellular Ca
2+. The EP2 and EP4 receptors are coupled
to adenylate cyclase through a Gas protein, increasing the cyclic
adenosine monophosphate (cAMP) level. The EP3 receptor has several
splice variants capable of coupling to different G-proteins thereby
contributing to the wide spectrum of EP3 actions. However, the
majority of EP3 isoforms couple to Gai inhibiting adenylate cyclase
and the production of cAMP [11].
In the present study, we have assessed the expression of the
PGE2 receptors in neuroblastoma, and the role of PGE2 signaling
in neuroblastoma survival and proliferation.
Materials and Methods
Human tissue samples
Neuroblastoma tumor tissue was obtained during surgery and
stored in 280uC. Tissue samples from 28 neuroblastoma patients
from all clinical stages [4] and different biological subsets were
analyzed [12]. Ethical approval was obtained from the Karolinska
University Hospital Research Ethics Committee (Approval
no. 2009/1369-31/1 and 03-736). Informed consent for using
tumor samples in scientific research was provided by parents/
guardians. In accordance with the approval from the Ethics
Committee the informed consent was either written or verbal.
When verbal or written assent was not obtained the decision was
documented in the medical record.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue slides were
deparaffinized in xylol and rehydrated in graded alcohols. For
antigen retrieval, slides were boiled in a sodium citrate buffer
(pH 6.0) for 10 min, in a microwave oven. After blocking in 1%
bovine serum albumin (BSA) for 20 min, the tissue sections were
incubated with primary antibody overnight, against EP1, EP2,
EP3 and EP4, respectively (Cayman Chemical, Ann Arbor, MI,
USA) diluted 1:250 in 1% BSA/PBS. Thereafter slides were rinsed
in PBS and endogenous peroxidases were blocked in 0.3% H2O2
for 10 min. As a secondary antibody, anti-rabbit-horseradish
peroxidase (HRP) SuperPicTure Polymer detection kit was used
(Invitrogen, Paisley, UK). All slides were counterstained with
haematoxylin. To control for non-specific binding, antibody
specific blocking peptides and isotype-matched controls were used.
Chemicals and solutions
Celecoxib was from Pfizer (Ta ¨by, Sweden). AH6809, AH23848,
16,16-dimethyl PGE2 (dmPGE2), PGE2, PGD2 and PGE2-d4 were
purchased from Cayman Chemical. L-161,982 and SC-51322
were obtained from BioMol (Plymouth Meeting, PA, USA).
ONO-8713 and ONO-AE3-240 were a generous gift from Ono
Pharmaceutical (CO., Ltd., Osaka, Japan). Arachidonic acid was
purchased from Nu-Check Prep (Elysian, MN, USA). 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoleum bromide (MTT)
was purchased from Sigma-Aldrich (Stockholm, Sweden). An-
alytical grade n-hexane, ethyl acetate, ammonium acetate and
HPLC grade methanol were supplied by Merck (Darmstadt,
Germany). 2,6-Di-tert-butyl-4-methylphenol (BHT) and citric acid
were purchased from Fluka (Sigma-Aldrich).
Cell lines
The human neuroblastoma cell lines, SH-SY5Y, SK-N-FI, SK-
N-SH, SK-N-BE(2), SK-N-AS, SK-N-DZ and IMR-32 were
cultured as previously described [3]. The human myelocytic cell
line, U-937 (ATCC, Boras, Sweden), was grown in PRMI using
the same supplements as mentioned above.
Reverse transcriptase-polymerase chain reaction
RNA was extracted from cells using TRIZOL reagent (Life
Technologies Inc.,Carlsbad, CA, USA) according to the manufac-
turer’s protocol, and cDNA was synthesized from 2.0 mgo fR N A
using a SuperScript Preamplification Kit (Life Technologies Inc.).
The PCR was performed in 50 mL of reaction mixture containing
4 mlc D N Af o rE P 1 - 4 ,a n d2mlf o rb-Actin (for SK-N-SH 4 mLw a s
used), 1 unit of DyNAzymeII Recombinant DNA (FinnzymesOy,
Espoo, Finland) and 1 mM of each primer. Samples prepared for
detection of EP1-3 were heated for 5 min at 94uCa n da m p l i f i e df o r
40 cycles of 30 s at 94uC, 1 min at 62uC, and 1 min at 72uC, and
finally for 10 min at 72uC. For the detection of EP4, samples were
amplified for 40 cycles of 45 s at 94uC, 1 min at 66uCa n d4 5sa t
72uC, while for b-actin the amplification was performed in 40
cycles of 1 min at 94uC, 1 min at 55uCa n d1m i na t7 2 uC. Primer
sequences were as follows: EP1 forward: 59-TGGGCCAG
CTTGTCGGTA-3; and reverse: 5-AGGGCCACCAACACCAG-
39;E P 2f o r w a r d :5 9-TGGGTCTTTGCCATCCTT-3; and reverse:
5-TCCGACAACAGAGGACTG-39; EP3 forward: 59-CAGCT-
TATGGGGATCATG-39; and reverse: 5-TCCGTG TGTGT
CTTGCAG-3; EP4 forward: 5- TCGCGCAAGGAGCAGAAG-
GAGACG-3; and reverse: 59-GGACGGTGGCGAGAATGAG-
GAAGG-39. b-Actin forward: 59- TGACGGGGTCACCCA-
CACTGTGCCCATCTA-39; and reverse: 59-ACTCGTCATA
CTCCTGCTTGCTGATCCA-39. PCR amplifications were per-
formed in a PTC-200 Peltier Thermal Cycler (MJ Research Inc.
Waltham, MA, USA). PCR products were analysed by agarose gel
electrophoresis and photographed under UV light.
Western blot analysis
For the detection of EP1-4, cells were lysed in RIPA buffer (Cell
Signaling, Beverly, MA, USA) containing protease inhibitors
(Roche Diagnostics GmbH, Mannheim Germany). Equal amounts
of protein were separated by SDS-PAGE (Lonza, In vitro),
transferred to nylon membranes (Millipore, Sundbyberg, Sweden)
and probed with antibodies against EP1, EP2, EP3, EP4 (Cayman
Chemical) or b-actin (Sigma-Aldrich), respectively. Anti-rabbit
IgG conjugated with HRP (Cell Signaling) was used as a secondary
antibody and Pierce Super Signal (Pierce, Rockford, IL, USA) was
used for detection. The experiments were repeated twice. To
investigate activation of the Akt signaling pathway by PGE2, SK-
N-BE(2) and SK-N-SH cells were incubated in RPMI supple-
mented with L-glutamine, penicillin G and streptomycin, for 24 h
before the addition of dmPGE2. After 1, 2, 4, 6, 12 or 24 h, cells
were trypsinized, washed in cold PBS and lysed in RIPA buffer
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tors, 1 mmol/L NaF and 1 mmol/L NaO3V4. Membranes were
probed with antibodies against phospho-Akt (ser473, Cell
Signaling), Akt, or b-actin, respectively. Anti-rabbit-HRP served
as a secondary antibody and a Pierce Super Signal was used for
detection. Each experiment was repeated three times.
Immunofluorescence
SH-SY5Y cells were grown on fibronectin coated chamber
slides (Nunc, Roskilde, Denmark) for 24 h. Cultures were washed,
and fixed with 2% paraformaldehyde for 15 min, followed by 70%
cold methanol for 5 min. After washing with PBS, sections were
incubated overnight at 4uC with rabbit-anti EP1-4 antibodies,
respectively. After rinsing in PBS, cells were incubated with
secondary antibodies conjugated with Alexa 488 (Invitrogen),
mounted with medium containing DAPI and analysed in
fluorescence microscopy. Image J software was used to merge
the pictures (NIH, Bethesda, USA).
Liquid-liquid extraction and LC-MS/MS analysis
Cells were cultured ina clear OptiMEMmedium(Gibco, Paisley,
UK) supplemented with 20% fetal bovine serum, L-glutamine,
penicillin G, and streptomycin, both with or without 40 mMo f
arachidonic acid, and 10 ng/mL of IL-1b (R&D Systems,
Abingdon, UK). Cells were harvested, washed and resuspended in
Ca
2+ and Mg
2+ free-PBS supplemented with protease inhibitors,
and sonicated three times for 10 s on ice. The homogenates were
further incubated in 80 mM of arachidonic acid for 30 min at 37uC.
Samples, standards and controls were extracted as previously
described [13] in 4.5 ml polypropylene tubes (Sarstedt, Germany).
Stock solutions were prepared in methanol to obtain a concentra-
tion of 1404 mmol/L for PGE2 and PGD2, and standard samples
were prepared by dilution of the stock solution in PBS at a
concentration ranging from 1–512 nM. Quality control samples
were prepared in the same manner. The residue was then
reconstituted in an 80 ml mobile phase and analyzed on a Waters
Acquity UPLC (Waters Corp., Milford, MA, USA) interfaced to a
WatersQuattroPremierXEtandemquadrupolemassspectrometer
(Waters Corp).The system was controlled by MassLynx version 4.1.
The chromatography was performed on a 2.16100 mm Waters
Acquity HSS T3 (C18) UPLC column maintained at 50uC with a
programmed gradient from solvent A (methanol/water/ammoni-
um acetate of 10/90/2 mM, v/v/concentration) to B (methanol/
water/ammonium acetate 90/10/2 mM, v/v/concentration) at
0.4 ml/min to resolve the PGE2 from PGD2. The flow was diverted
to waste before and after the analytes of interest. The mass
spectrometer was operated in a negative electrospray ion mode, and
the spray voltage was 3 kV. The sample injection volume was 15 ml
and the injection interval was 7 min. The autosampler temperature
was 5uC; desolvation gas temperature 340uC; source temperature
120uC; desolvation gas flow 900 L/h; cone gas flow 40 L/h;
collision gas pressure 3.5610
23 mBar (argon); ion energies, 0.9 V
for both quadrupoles. For quantitative analysis of PGE2, the
following MRM transitions were used: m/z 351R315 (quantifica-
tion ion), 351R271 (qualifier ion) and 351R315 (qualifier ion).
MRM transition m/z 355R319 and 355R275 were used for the
internal standard. The dwell time was set to 20 ms for each
transition. The method demonstrated a good linearity and
reproducibility with a correlation coefficient (r
2)o f.0.99 and a
coefficient of variation of ,10%.
Intracellular calcium mobilization
The intracellular mobilization of calcium in response to dmPGE2
was visualized by the fluorescent calcium dye Fluo-4/AM (Invitrogen)
a n dm e a s u r e du s i n gac o n f o c a ll a s e rscanning microscope (Zeiss LSM
510 META). SK-N-SH (4610
5cells) cells were seeded on cover slips in
Petri dishes and cultivated overnight before incubation for 30 min at
37uC in Krebs-Ringer solution (119 mM NaCl, 2.5 mM KCl,
1.0 mM NaH2PO4 (monobasic), 2.5 mM CaCl2?2H2O,1.3 mM
MgCl2?6H2O, 20 mM Hepes, 11 mM D-glucose C6H12O6,p H7 . 4 )
containing 5 mM Fluo-4/AM. Thereafter, cells were washed with
Krebs-Ringer solution and subsequently examined with a confocal
laser scanning microscope. Before 1 mMo fd m P G E 2 was bath-applied
a base line was determined, with or without 2 mM of EGTA (Sigma-
Aldrich), for 5 min for each sample that was analysed. Images were
processed and analysed using the Image J software.
Cyclic AMP
The intracellular level of cAMP was determined using a cAMP
EIA kit (Cayman Chemical). SK-N-SH cells (1.5610
6) were
seeded in 10 cm
2 Petri dishes and cultivated for 48 h. Cells were
grown in RPMI supplemented with L-glutamine, penicillin G, and
streptomycin overnight before the addition of 1 mM dmPGE2
for 2.5, 5, 10 or 20 min, or 10 mM forskolin (Enzo, Plymouth
Meeting, PA, USA) for 10 min. As a negative control, cells were
pre-treatment with 10 mM NF 449 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) for 60 min before the addition of dmPGE2
for 10 min. The plates were rinsed with PBS, and lysed using
500 mL 0.1 M HCl for 20 min at room temperature. The plates
were scraped and the lysates were collected and centrifuged. The
supernatants were acetylated and used for intracellular cAMP
determination according to the manufacturer’s instructions.
Cell viability assay
The effect of dmPGE2 on neuroblastoma cell viability was
investigated using the MTT-assay [14]. SK-N-BE(2) (3610
3 cells/
well) and SK-N-SH (2610
4 cells/well) cells were seeded in 96-well
plates. After 24 h, the medium was changed to RPMI supplemented
with L-glutamine, penicillin G, and streptomycin. After 24 h, an
increasing concentration of dmPGE2 was added and the cells were
further incubated for 24, 48, 72 and 96 h, respectively before
subjected to MTT-assay. The medium was changed every second day
and the mean values of optical density measurements of six separate
wells were calculated. To determine the effect of dmPGE2 on
cytotoxicity mediated by COX-2 inhibition, 1610
4SK-N-BE(2) cells/
well were seeded in 96-well plates. After 24 h of incubation the
medium was changed and dmPGE2 alone or in combination with
celecoxib diluted in serum-free OptiMEM medium (Gibco) supple-
mented with L-glutamine, penicillin G, and streptomycin, was added.
After 48 h, cell viability was measured using MTT-assay. To evaluate
the effect ofPGE2receptorantagonistson neuroblastoma cell viability,
cells were incubated in 96-well culture plates with an increasing
concentration of drug for 48 h. All reagents were dissolved in DMSO
and further diluted in OptiMEM using the same supplements as
above (the final DMSO concentration was always ,0.5%).
Statistical analysis
Two-sided unpaired t-test was performed to evaluate the
accumulation of cAMP and the effect of dmPGE2 addition to
celecoxib-treated cells. A two-way ANOVA was used to evaluate
the effect of dmPGE2 on neuroblastoma cell viability.
Results
All four PGE2 receptor subtypes are expressed in
neuroblastoma primary tumors and cell lines
We stained 28 neuroblastomas from all different clinical stages
and biological subsets with antibodies detecting EP1, EP2, EP3
Prostaglandin E2 Signaling in Neuroblastoma
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the four receptor subtypes in tumor cells in addition to a certain
degree in endothelial cells in the adjacent stromal compartment
(Figure 1A). The staining was evident both in the cytoplasm and
the nucleus. There was no apparent staining with any of the
antibodies when pre-incubated together with respective blocking
peptide, hence confirming the specificity of the antibodies using
this protocol (Figure 1B). In addition, seven neuroblastoma cell
lines, with different genetic aberrations and biological features
were investigated and all showed expression of mRNA and protein
for EP1-4 (Figures 1C and D). Further analyses of EP1-4
expression pattern by immunofluorescence revealed an expression
of the receptors in cellular membranes as well as in cytoplasmic
vesicles (Figure 1E). The EP1 and EP4 receptors were also shown
to be present in the nuclear compartment (Figure 1E).
Neuroblastoma cells produce PGE2 and dmPGE2 induces
proliferation and survival of neuroblastoma cells
Since COX-2 and the PGE2 receptors are expressed in
neuroblastoma, we investigated the production of PGE2 and its
effects on cell growth. The MYCN-amplified, drug-resistant cell line
SK-N-BE(2) produced PGE2 under normal culture conditions,
whereas SK-N-SH cells did not produce detectable levels
(Figure 2A). By culturing the cells with arachidonic acid, which is
the substrate for prostaglandin biosynthesis, both cell lines were
shown to produce PGE2 and stimulation with IL-1b further
increased the production (Figure 2A). The addition of dmPGE2 to
serum-starved SK-N-BE(2) and SK-N-SH cells resulted in an
increased cell viability and proliferation in a dose-, time- and cell
line-dependentmanner(p,0.0001,Figure2B).Theeffectwas more
pronounced for the SK-N-BE(2) cells because of the reduced cell
growth of serum starved controls. We have previously shown that
the inhibition of COX-2 with celecoxib, at concentrations above
28 mM, significantly reduces neuroblastoma cell viability [3]. To
investigate whether exogenously added dmPGE2 could rescue
neuroblastoma cells from celecoxib-induced toxicity we treated SK-
N-BE(2) cells with 35 mM celecoxib alone or in combination with
1 mM of dmPGE2. As shown in Figure 2C, dmPGE2 completely
abrogated celecoxib-mediated cytotoxicity (p,0.0001).
Addition of dmPGE2 increases the intracellular
concentrations of calcium and cAMP with a subsequent
phosphorylation of Akt in neuroblastoma cells
EP1-4 are coupled to G-proteins that activate various second
messengers and signaling cascades. In the responding SK-N-SH
cells, the addition of dmPGE2 resulted in a rapid increase in the
cytoplasmic level of Ca
2+. Pre-incubation with the calcium
chelator EGTA did not alter the response, thus demonstrating
that Ca
2+ is released from intracellular stores (Figure 3A and B).
The addition of dmPGE2 to SK-N-SH cells also resulted in a
significantly increased concentration of cAMP after 20 min of
incubation (p,0.05, Figure 3C). The concentration was in the
same range as after 10 min of incubation with forskolin, known to
specifically activate adenylate cyclase. In addition, the Gas
inhibitor NF 449 inhibited dmPGE2-mediated production of
cAMP. Moreover, the addition of dmPGE2 to serum-starved SK-
N-SH and SK-N-BE(2) cells resulted in a sustained phosphoryla-
tion of Akt(ser 473), (Figure 3D).
Inhibition of PGE2 receptor signaling reduces
neuroblastoma cell viability
To evaluate the importance of each of the PGE2 receptor
subtypes for neuroblastoma cell viability we incubated cells with a
panel of receptor antagonists (Table 1). Inhibition of the EP1
receptor resulted in a 50% reduced cell viability (EC50)a t8 –
20 mM of the non-prostanoid compound ONO-8713, and at 35–
50 mM of SC-51322, which has been widely used for EP1 receptor
characterization [15]. To the best of the authors knowledge,
specific receptor antagonists for EP2 are not commercially
available, however, the widely used AH6809 has an affinity not
only for the EP2 receptor but also for EP1 and the PGD2 receptor
1, and the selectivity is poor at concentrations in the micromolar
range [15]. The EC50 value on neuroblastoma cell viability for
AH6809 ranged from 30 mMt o.100 mM. Incubation with the
highly selective EP3 receptor antagonist, ONO-AE3-240, resulted
in an EC50-value of 7.5–22.5 mM. We also treated cells with two
different EP4 receptor antagonists and the EC50 range was 10–
20 mM and 30 to .100 mM, for L-161,982 and AH23848,
respectively.
Discussion
Upregulation of COX-2 and an increased PGE2 level are
frequently detected in premalignant and malignant tissues of
epithelial origin in adults. Several experimental, epidemiological
and clinical studies suggest that COX inhibitors have a potential as
chemopreventive therapy by reducing chronic inflammation that
predispose cancer development [1]. Further studies have revealed
that PGE2 possess various of important effects attributed to tumor
growth such as increased proliferation, angiogenesis, metastasis
and immune suppression [1]. Whether PGE2 exerts the same
effects in childhood tumors is not yet clear. Recent therapeutic
phase III studies in adults, using COX- 2 inhibitors in an adjuvant
setting of colorectal cancer and non-small cell lung cancer, showed
no significant survival benefit [16,17]. Therefore, additional
studies investigating the link between PGE2 and cancer and the
potential of a more specific targeting of prostaglandin signaling are
needed. We have previously reported high COX-2 expression in
neuroblastoma, a childhood tumor of the sympathetic nervous
system, and medulloblastoma, in the central nervous system, and
showed a pronounced effect with COX inhibitors in treatment in
vivo [3,5,18]. However, no studies have addressed the specificity of
COX-2 inhibition in neuroblastoma or the function of its major
end product PGE2.
By immunohistochemistry, we detected expression of all four
PGE2 receptor subtypes, EP1, EP2, EP3 and EP4, in the tumor
cells of all primary neuroblastomas investigated, independent of
any biological characteristics or clinical stage (Figures 1A and
B).The receptors were also expressed in the vasculature of the
adjacent stromal tissue. Furthermore, mRNA and protein
corresponding to EP1-4 were found to be expressed in all seven
neuroblastoma cell lines, exhibiting different genetic aberrations
and biological features ([19], Figures 1C and D). The EP2 receptor
has previously been shown to be epigenetically silenced in
preferentially MYCN-amplified neuroblastoma tumors and cell
lines, and therefore suggested to act as a tumor suppressor in
aggressive neuroblastomas [20]. We could not find this suggested
correlation in either our clinical patient material including several
tumor samples with MYCN amplification, or cell lines derived from
high-risk patients with or without MYCN amplification. In
addition, when using the publicly available R2 microarray analysis
and visualization platform with expression array data from 88
neuroblastoma tumors (available at http://r2.amc.nl [21],) EP2
mRNA expression was significantly correlated with poor clinical
outcome with highest expression found in MYCN-amplified tumors
(data not shown). An increased EP receptor expression has been
reported in medulloblastoma, and in various adult epithelial
Prostaglandin E2 Signaling in Neuroblastoma
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receptors and the expression pattern seems to be dependent on the
tumor type [18,22–28].
In addition to the conventional restriction of GPCR expression
to the cell membrane, the PGE2 receptors have been reported to
be localized in the nuclear membrane and we therefore
investigated the cellular localization of the receptors in neuroblas-
toma cells by immunofluorescence [10,29]. We detected EP1-4 in
the cellular membrane and in vesicles in the cytoplasm (Figure 1E).
Besides, EP1 and EP4 were also shown to be present in the nuclear
compartment (Figure 1E). The presence of nuclear EP receptors
suggests that in addition to a conventionally autocrine or paracrine
manner, PGE2 may be capable of acting intracellularly, thereby
potentially influencing nuclear events [30]. Interestingly, EP1 is
expressed both in the cytoplasm and nucleus of breast cancer cells
and a nuclear expression of EP1 is associated with a better
prognosis for these patients [31].
We also demonstrate that neuroblastoma cells are able to
produce PGE2, and that incubation with arachidonic acid or IL-
1b increases the production (Figure 2A). These results show a
functional COX pathway that can be triggered by inflammatory
stimuli, suggesting a prominent role for COX-2 in the production
of PGE2 in neuroblastoma cell lines. Importantly, PGE2 is a potent
proinflammatory molecule involved in the crosstalk between
tumor cells and infiltrating immune cells. In the tumor
microenvironment, production of PGE2 by neuroblastoma cells
may contribute to inflammation and immune suppression [1]. To
further explore the effect of PGE2 on neuroblastoma cell viability,
dmPGE2 was added to serum-starved neuroblastoma cell cultures
that stimulated neuroblastoma cell proliferation and survival in a
dose-, time- and cell line-dependent manner (Figure 2B). These
results extend our earlier study demonstrating a dose-dependent
effect on the proliferation of medulloblastoma cells [18]. The toxic
effect of celecoxib was also attenuated by dmPGE2 suggesting an
Figure 1. Neuroblastoma expresses all four PGE2 receptors. (A) Immunohistochemistry showing specific expression of EP1-4 in tumor cells of
a primary human neuroblastoma. (B) Antibody specific blocking peptides were used to control for non-specific binding. Magnification 6400. (C) RT-
PCR detecting EP1-4 mRNA in human neuroblastoma cell lines. The myelocytic cell line, U-937, was used as positive control. b-actin was used to
ensure equal cDNA load. (D) Western blot detecting bands at 42, 52, 52 and 65 kDa corresponding to EP1, EP2, EP3 and EP4, respectively, in protein
extracts from human neuroblastoma cell lines. U-937 cells were used as a positive control. b-actin was used to ensure equal protein loading. The
western blots are representative of two independent experiments. (E) Immunofluorescence staining identifying EP1 and EP4 receptor expression in
the cellular membrane, in the cytoplasm, and in the nuclear membrane of neuroblastoma cells. EP2 and EP3 were detected in the cellular membrane
and in the cytoplasm. Cells were double stained with DAPI to visualize cell nucleus. Magnification 6400.
doi:10.1371/journal.pone.0029331.g001
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toma (Figure 2C).
Given the fact that neuroblastoma cells produce PGE2 as well as
the complexity that follows the expression of all four receptor
subtypes, we decided to investigate the effect of exogenously added
dmPGE2 on intracellular signaling pathways. Signal transduction
downstream of the different EP receptor subtypes has been studied
by agonist-induced alterations of second messengers and these
studies indicate that the receptors do not exclusively couple to one
G-protein and one downstream signaling pathway [11]. In
addition, not only the Ga subunit is important in cell signaling,
as the bc subunits also interact with and stimulate downstream
effectors [32]. In neuroblastoma, dmPGE2 increased the cytoplas-
mic Ca
2+ level by its release from intracellular Ca
2+ stores. We also
detected a significant increase in cAMP which was inhibited by
pre-treatment with a Gas inhibitor. These results indicate that
neuroblastoma cells respond to PGE2 by activation of more than
one EP receptor, followed by a subsequent stimulation of an
intracellular Ca
2+ release and production of cAMP. Calcium
release is predominantly a result of the activation of EP1, but due
to the different splice variants of the EP3 receptor, this receptor is
capable of coupling with several different G-proteins including
Gaq which stimulates Ca
2+ mobilization [33]. The stimulation of
adenylate cyclase and cAMP is primarily a result of the activation
of EP2 and/or EP4. The EP3 receptor has also been shown to be
able to couple to Gas, whereas the major splice variant couples to
Gai, thus inhibiting cAMP production [11]. Calcium is a
ubiquitous second messenger and its cellular concentration and
distribution are strictly regulated. In cancer, Ca
2+ has been
implicated in several important features of tumorigenesis including
motility, angiogenesis, transcription, differentiation, cell cycle
regulation and apoptosis [34]. Moreover, Ca
2+ activates cPLA2
that subsequently releases arachidonic acid [35]. The effect of
cAMP is mediated by cAMP-dependent protein kinase A (PKA)
and the exchange proteins activated by cAMP (EPACs). The role
of cAMP-PKA and -EPACs in cancer appears to be dependent on
the cell type. The activation of these proteins has been shown to
either stimulate cell proliferation, or reduce cell growth and
promote differentiation [36,37]. The role of cAMP in neuroblas-
toma is not fully elucidated, though it has been shown that
neuroblastoma cells contain a low level of cAMP and that the
treatment with a cAMP analog induces differentiation in vitro [38].
Furthermore, the production of cAMP in response to PGE2 is
increased in retinoic acid-differentiated SK-N-BE(2)C cells [39].
The activation of G-proteins initiates further intracellular
signaling, which is mediated either by Ga and a change in second
messengers or by the bc subunits. In epithelial cancers, PGE2 has
been shown to activate important signaling pathways involved in
proliferation and survival such as PI3K/Akt, MAP-kinases, Wnt
and transactivation of EGFR [1]. In neuroblastoma, the majority
Figure 2. Neuroblastoma cells produce PGE2 and dmPGE2 increases cell viability. (A) Neuroblastoma cells produce PGE2. SK-N-BE(2) and
SK-N-SH cells were cultured with or without 40 mM of arachidonic acid (AA) for 48 h and 10 ng/mL IL-1b for 12 h. Cell homogenates were incubated
with 80 mM of arachidonic acid and the concentration of produced PGE2 was measured using LC-MS/MS. (B) PGE2 increases neuroblastoma cell
viability. SK-N-BE(2) and SK-N-SH cells were incubated in a serum-free medium for 24 h before adding different concentrations of dmPGE2. Cell
viability was measured using MTT-assay after 24, 48, 72 or 96 h. Values are representative of two independent experiments and data are expressed as
mean (6SD) in percentage of control at 24 h. A statistical analysis was performed using 2-way ANOVA p,0.0001 for both concentration and
incubation time. (C) PGE2 rescues neuroblastoma cells from celecoxib induced apoptosis. SK-N-BE(2) cells were incubated in 35 mM celecoxib alone or
in combination with 5 mM dmPGE2. After 48 h cell viability was assessed using MTT-assay. Mean (6SD) of six replicate wells is shown; values are
representative of three independent experiments. Statistical analysis was performed using 2-sided t test P,0.0001.
doi:10.1371/journal.pone.0029331.g002
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degree of phosphorylation correlates with a poor prognosis
[40,41]. We and others have shown that inhibition of Akt
signaling induces apoptosis and reduces neuroblastoma tumor
growth [40–44]. These studies reveal that Akt is a promising novel
target for neuroblastoma therapy [45]. The addition of dmPGE2
to serum-starved neuroblastoma cell cultures, resulted in an
increased phosphorylation of Akt (Ser473) that was sustained after
24 h of incubation (Figure 3D). The activation of Akt can trigger
many downstream signaling cascades, and in colon cancer PGE2
has been shown to activate Akt and the downstream pathway of
GSK-3b and b-catenin resulting in an increased proliferation,
whereas an increased survival was due to Akt activation of PPARd
[46,47]. Activation of the Akt signaling pathway could explain the
mechanism underlying the positive effect of PGE2 on neuroblas-
toma cell viability.
We also investigated the effect of PGE2 receptor antagonists on
neuroblastoma cell viability (Table 1). The most effective drugs in
reducing cell viability were ONO-8713, ONO-AE3-240, and L-
161,982 targeting the EP1, EP3 and EP4 receptors, respectively.
These results suggest that more than one receptor is important for
neuroblastoma cell viability. However, the results are also
Figure 3. dmPGE2 increases intracellular Ca
2+ and cAMP concentrations followed by phosphorylation of Akt. (A) Intracellular calcium
mobilization in response to dmPGE2. SK-N-SH cells were loaded with the calcium fluorescent dye Fluo-4/AM before the addition of 1 mM dmPGE2 or
(B) pre-treatment with 2 mM EGTA before exposure to 1 mM dmPGE2. The fluorescence intensity was followed using a confocal laser scanning
microscope and representative single-cell recordings are shown. The arrows indicate when dmPGE2 is added. (C) Intracellular accumulation of cAMP
in response to dmPGE2. SK-N-SH cells were incubated overnight in a medium without serum before the addition of 1 mM of dmPGE2. Pretreatment
with 10 mM NF 449, which is a Gas inhibitor, before the incubation in dmPGE2 for 10 min inhibited the production of cAMP. Forskolin, 10 mM for
10 min, was used as a positive control. The graph shows mean (6SD) in % of untreated control of three independent experiments. A statistical
analysis was performed using 2-sided t-test, P,0.05. (D) PGE2 induces phosphorlyation of Akt. SK-N-BE(2) and SK-N-SH cells were grown in the
presence of serum (Ctr) before 24 h of culturing in the absence of serum (0 h) prior to the addition of 1 mM of dmPGE2. Cells were further incubated
in dmPGE2 for 1, 2, 4, 6, 12 or 24 h and protein extracts were subjected to western blotting to detect phosphorylated Akt(ser473). An antibody
detecting unphosphorylated Akt was used to exclude differences in total protein expression. b-actin was used to control for equal protein loading.
The western blots are representative of three independent experiments.
doi:10.1371/journal.pone.0029331.g003
Table 1. EC50 of EP1-4 receptor antagonists on neuroblastoma cell viability in vitro.
EC50 (mM)
Drug Drug target SK-N-SH
b SH-SY5Y SK-N-AS
b SK-N-FI
b IMR-32
a SK-N-BE(2)
a,b
ONO-8713 EP1 12–14 12–14 12–14 18–20 10–12 8–10
SC-51322 EP1 35–40 35–40 40–45 45–50 40–45 35–40
AH6809 EP1, EP2, DP1 45–60 30–45 .100 60–75 45–60 75–90
ONO-AE3-240 EP3 10–12.5 7.5–10 12.5–15 20–22.5 12.5–15 7.5–10
AH23848 EP4, TP 40–50 30–40 .100 60–70 30–50 70–80
L-161,982 EP4 10–15 5–10 10–15 15–20 10–15 10–15
Abbreviations: EC50; effective concentration decreasing neuroblastoma cell viability with 50%,
aMYCN amplification;
bMultidrug-resistant phenotype.
doi:10.1371/journal.pone.0029331.t001
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antagonist for the receptor [15]. The complex expression pattern
of the PGE2 receptors in neuroblastoma, as well as in other
cancers, makes it difficult to dissect the importance of a specific
receptor. Several studies indicate that the receptors may play
different roles in tumorigenesis [48–50]. A study using the Apc
1309
mouse model shows that treatment with the EP1 antagonist,
ONO-8711, reduces the number of intestinal polyps whereas
treatment with an EP4 antagonist results in smaller polyp size.
Furthermore, treatment with the two antagonists in combination
shows an additive effect on the number and size of intestinal
polyps [51].
Taken together, our results demonstrate that PGE2 is produced
in neuroblastoma and that the PGE2 receptors are abundantly
expressed, hence constituting an autocrine and/or paracrine
survival loop of significance for tumor growth and spread of this
childhood tumor. Thus, strategies based on selective targeting of
PGE2 signaling could be an alternative therapeutic approach
against this cancer that could avoid the otherwise potential side
effects of COX-2 inhibitors.
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